Credit Suisse Ag Novavax Inc Call Options Transaction History

Credit Suisse Ag

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $12.4 Million - $20.1 Million	92,000 Added 359.38%	117,600 $16.8 Million
Q3 2021 Nov 12, 2021	SELL	$177.8 - $270.58 $160,020 - $243,522	-900 Reduced 3.4%	25,600 $5.31 Million
Q2 2021 Aug 16, 2021	BUY	$121.0 - $257.67 $750,200 - $1.6 Million	6,200 Added 30.54%	26,500 $5.63 Million
Q1 2021 May 14, 2021	BUY	$112.98 - $319.93 $2.29 Million - $6.49 Million	20,300 New	20,300 $3.68 Million

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $680M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.